Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| AMD | Digital Realty Trust | Moderna | |
|---|---|---|---|
| Moat rating | narrow AMD's FY2025 10-K documents real but bounded advantages: approximately 7,200 U.S. patents and roughly 18,900 patent matters worldwide, an outright claim that 'We are the market share leader in semi-custom game console products,' and gross margin of 50% on revenue up 34% to $34.6 billion. The same filing sets the ceiling: 'Some of our competitors may possess stronger market positions, larger customer bases, more design wins, and greater financial, sales, marketing, and distribution resources than us'; Nvidia is named 'the discrete GPU market share leader'; and AMD relies on TSMC 'for the production of all wafers for microprocessor and GPU products at 7 nanometer (nm) or smaller nodes.' Advantages that are genuine, contested, and dependent on a shared foundry are narrow, not wide. | narrow The FY2025 10-K's own competitive record cuts both ways. Item 1 says a "high-quality, highly interconnected global portfolio such as ours could not be easily replicated today on a cost-competitive basis," yet Item 1A concedes that competitors have "significantly greater financial, marketing and other resources and more ready access to capital" and that as rivals keep developing space, "rental rates may be reduced or we may face delays in leasing." A durable advantage that its own filing says new supply can price against is bounded, not unassailable. | narrow The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion. |
| Moat type | intangibles ip The FY2025 10-K locates the durable asset in design IP rather than manufacturing: 'We rely on contracts and intellectual property rights to protect our products and technologies from unauthorized third-party copying and use,' with approximately 7,200 U.S. patents and about 18,900 patent matters worldwide spanning x86 EPYC/Ryzen CPUs, CDNA/RDNA graphics and the Versal/Zynq adaptive-SoC families, and it credits customer wins to 'our broad IP portfolio and leadership in design, integration and advanced packaging.' It is explicitly not cost_scale: AMD is fabless and 'utilize[s] Taiwan Semiconductor Manufacturing Company Limited (TSMC) for the production of wafers' — the same leading-edge foundry its merchant competitors use, so no manufacturing-scale advantage accrues to it. | network effects Item 1 attributes the hard-to-replicate part of the portfolio to connectivity rather than to real estate: "the network density, interconnection infrastructure and connectivity-centric customers in certain of our data centers have led to the organic formation of densely connected data communities that are difficult for competitors to replicate." That community sits on over 232,000 cross connects in over 55 metros, so each network and cloud that lands makes the same building worth more to the next tenant. | intangibles ip The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power." |
| Leadership | fast follower The FY2025 10-K itself places AMD behind the pace-setter in its two most important markets: 'Our principal competitor in the supply of discrete graphics is Nvidia, who is the discrete GPU market share leader,' and the risk factors state Nvidia 'leverages its market position in data center GPU, financial resources, and proprietary software ecosystem to promote its systems and influences customers who do business with us.' AMD is nonetheless executing 'an annual cadence of leadership for AMD Instinct solutions' and has won gigawatt-scale commitments (OpenAI, 6 GW) — following fast and closely, not setting the pace. | co leader Item 1 claims the title of "the largest global provider of cloud- and carrier-neutral data center, colocation and interconnection solutions," but the Competition section names Equinix and NTT as operators of properties "similar to ours in some of the same metropolitan areas," plus Global Switch and regional operators abroad — a shared top tier on the company's own telling, not a solitary one. | co leader The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date." |
| Pricing power | moderate FY2025 gross margin was 50%, up from 49% in 2024 per the 10-K — healthy and improving — but the same filing attributes average-selling-price pressure to competitors: Intel 'uses its microprocessor market position to price its products aggressively and target our customers and channel partners with special incentives. These aggressive activities have reduced and may reduce our unit sales and average selling prices for many of our products'. Pricing power is real but contested. | strong FY2025 renewals signed re-priced upward in every bucket — +27.0% on greater-than-1 MW space ($146 to $186 per square foot), +4.6% on 0-1 MW ($268 to $280) and +43.0% on other ($49 to $71) — and MD&A expects average aggregate rental rates on 2026 renewals to be positive against the rates currently paid for the same space "on a GAAP basis and on a cash basis." On costs, the filing says utilities expense "is our largest expense category" and that "the vast majority of the expense is passed directly through to our customers," which it credits with significantly mitigating exposure to power-cost increases rather than removing it. The cap: Item 1A warns competitor development could still force rates down. | weak Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries." |
| Summary | AMD's edge is architectural design IP executed on someone else's fabs. The FY2025 10-K describes a full-stack portfolio — EPYC server CPUs, Instinct AI accelerators, Ryzen client parts where 'AMD was the first company to integrate a dedicated neural processing unit (NPU) on the same SoC as an x86 CPU for AI PCs,' Radeon graphics, Pensando networking and Versal adaptive SoCs — backed by roughly 18,900 patent matters worldwide, and it discloses gigawatt-scale customer commitments (an October 2025 agreement with OpenAI 'to deploy 6 gigawatts of AMD GPUs,' first gigawatt on Instinct MI450). The same filing bounds that moat: Nvidia is 'the discrete GPU market share leader' and 'leverages its market position in data center GPU, financial resources, and proprietary software ecosystem'; Intel 'uses its microprocessor market position to price its products aggressively'; Arm architectures and customers who 'internally develop products to support similar AI workloads' are named as encroaching; and every wafer at 7 nm or below comes from TSMC. Revenue grew 34% in FY2025 with Data Center up 32%, but the filing's own competitive framing places AMD in the challenger seat rather than the entrenched one. | Digital Realty rents space, power and connectivity rather than compute: at 2025 year-end its portfolio held 310 data centers and roughly 57.6 million rentable square feet across more than 55 metros in over 30 countries, about 84.7% leased, serving more than 5,000 customers. Two different businesses sit inside that footprint. The greater-than-1 MW wholesale side is a capital-and-power race — 769 MW of projects underway with 64% pre-leased, and land that "could accommodate over 3,500 megawatts of additional data center capacity" — where the 10-K names Equinix, NTT, Global Switch and "various private operators" as rivals and warns that added supply can push rents down. The colocation and interconnection side is the defended half: over 232,000 cross connects and the "densely connected data communities" Item 1 says competitors cannot easily replicate, reinforced by contracts the filing describes as generally running 5-10+ years on large deployments and by improvements "installed at our customers' expense." FY2025 leasing supports that read — renewals signed re-priced +27.0% on greater-than-1 MW space and +4.6% on 0-1 MW — while customer concentration is the offsetting exposure, with the largest customer at roughly 11.7% of annualized recurring revenue. | Moderna's 10-K rests its competitive case on the mRNA platform and the IP wrapped around it: the company states it believes its capabilities "across mRNA technology, drug discovery, development and manufacturing" differentiate it, and reports more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed abroad, 485 pending applications, and granted patents on Spikevax, mNEXSPIKE and mRESVIA projected to expire in 2041 (U.S.) and 2036 (Europe), plus trade secrets and manufacturing know-how it calls substantial. The filing is equally direct about the limits: the principal COVID rival's vaccine "is also based on mRNA technology"; a competitor's European Commission contract keeps Moderna out of many European COVID markets until year-end 2026; RSV sales are "minimal to date" behind Pfizer and GSK; and the risk factors warn that "the mRNA medicines field is growing rapidly, with increased competitive pressure from large and more established pharmaceutical companies." What is durable is science and plant rather than commercial position: Moderna bought and operates the Norwood (MTC) campus, completed a Marlborough site purpose-built for intismeran autogene that began shipping patient batches in September 2025, and runs UK, Canada and Australia facilities that were fully licensed in 2025, each government having entered a multi-year commitment to purchase mRNA products from the company. |
| Chain position | A fabless merchant-silicon designer sitting one layer above the foundries: the FY2025 10-K states AMD relies on TSMC 'for the production of all wafers for microprocessor and GPU products at 7 nanometer (nm) or smaller nodes' and primarily on GLOBALFOUNDRIES above 7 nm, with packaging and test performed by Asia-Pacific ATMP partners — so its cost, supply and cadence are inherited from partners it does not control. | Landlord to the AI stack — sells the space, power and interconnection that cloud, network and enterprise tenants run compute in (Oracle, IBM, Meta Platforms, AT&T, Comcast and Lumen are among the customers named in Item 1), with roughly 2.9 GW of total in-place IT capacity. | A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.06 at weight 0.20 · swarm bullish Editorial prior, not backtested. | +0.17 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.05 at weight 0.20 · swarm bearish Editorial prior, not backtested. |